Cell- and Tissue-Based Therapy
"Cell- and Tissue-Based Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
| Descriptor ID |
D064987
|
| MeSH Number(s) |
E02.095.147
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cell- and Tissue-Based Therapy".
Below are MeSH descriptors whose meaning is more specific than "Cell- and Tissue-Based Therapy".
This graph shows the total number of publications written about "Cell- and Tissue-Based Therapy" by people in this website by year, and whether "Cell- and Tissue-Based Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 3 | 0 | 3 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 6 | 7 |
| 2023 | 1 | 3 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell- and Tissue-Based Therapy" by people in Profiles.
-
Value-based payment and financing for cell and gene therapies: challenges and potential solutions. J Med Econ. 2024 Jan-Dec; 27(1):678-681.
-
Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and Type 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Redosing Triggers. Am J Nephrol. 2024; 55(3):389-398.
-
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2023 09 12; 7(17):4765-4772.
-
Implementation of a gene therapy education initiative by the ASGCT and Muhimbili University of Health and Allied Sciences. Mol Ther. 2023 09 06; 31(9):2561-2565.
-
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023 Jun 09; 44(22):2029-2042.
-
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Rev. 2023 07; 60:101072.
-
Non-viral precision T?cell receptor replacement for personalized cell therapy. Nature. 2023 03; 615(7953):687-696.
-
Management of endothelial disease without keratoplasty. Curr Opin Ophthalmol. 2022 Jul 01; 33(4):332-337.
-
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 02 20; 41(6):1265-1274.
-
Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy. J Transl Med. 2022 05 23; 20(1):241.